TURNING PRECISION APTAMERS INTO A NEW ERA OF MEDICINE
We are harnessing the power of aptamers to develop life-changing treatments for neurodegenerative diseases and cancer.
Deaths
609,820
Cost of care
>$240B
Deaths
272,644
With rising diagnoses and escalating costs for cancer, the demand for effective treatments is more pressing than ever.
4.7 to 6.0 million individuals in the U.S. suffer from CNS diseases
2023 cost of care
$800 bn
Most treatments today only offer limited symptom management. And millions of patients are left without a cure.
The power of precision aptamers
Opprtna is advancing the therapeutic potential of premium aptamers.
1
Novel modality
Pioneering a novel drug modality that targets and stops disease-related proteins using DNA molecules.
2
Targeted and safe
Approach ensures targeted and safe delivery, transforming the treatment landscape for patients previously deemed untreatable.
3
Potential applications
Science holds promise as evidenced by initial success with select targets in neurodegenerative and oncology indications.
Leadership
A powerhouse of scientific excellence, disease expertise, and operational grit. We have built transformative departments and organizations, turning visionary ideas into tangible realities.
Advisors
Paloma Giangrande, PhD
CTO, Eleven Therapeutics
VP (Platform and Delivery), Wave Life Sciences
Editor in Chief, Mol Therap Nucleic Acids
Piet Herdwjn, PhD
Professor, KU Leuven - Laboratory of Medicinal Chemistry, Belgium
May Khanna, PhD
Co-Founder of Regulonix, LLC, Regenerix, LLC and Eternum Analytics, LLC
Assistant Dean and Associate Professor, Univ of Florida
Rachit Bakshi, PhD
Assistant Professor, Harvard Medical School
